Last reviewed · How we verify
AAV-hTERT
AAV-mediated delivery of the hTERT gene
AAV-mediated delivery of the hTERT gene Used for Telomere-related disorders.
At a glance
| Generic name | AAV-hTERT |
|---|---|
| Also known as | LGT |
| Sponsor | Libella Gene Therapeutics |
| Drug class | Gene therapy |
| Target | hTERT |
| Modality | Small molecule |
| Therapeutic area | Rare Disease |
| Phase | Phase 1 |
Mechanism of action
AAV vectors are used to deliver the human telomerase reverse transcriptase (hTERT) gene to cells, which can lead to the activation of telomerase and the extension of telomeres, potentially leading to the regeneration of cells and tissues.
Approved indications
- Telomere-related disorders
Common side effects
Key clinical trials
- Evaluation of Safety and Tolerability of Libella Gene Therapy for the Treatment of Aging: AAV- hTERT (PHASE1)
- Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT (PHASE1)
- Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AAV-hTERT CI brief — competitive landscape report
- AAV-hTERT updates RSS · CI watch RSS
- Libella Gene Therapeutics portfolio CI